Abstract
Diagnosis, evaluating symptom changes, and prognosis in schizophrenia are primarily based on complete history, structured interviews, and rating scales. Biomarkers are objectively measured indicators of normal biological or pathological processes which might indicate the presence and severity of an illness. Though the evidence for its clinical utility in predicting outcome and recovery in schizophrenia is still in its infancy, it is worthwhile to review available markers to enhance the understanding of this heterogeneous disorder. In this chapter we attempt to consolidate various clinical, neurochemical, neurophysiological, neuroimaging, neurocognitive, and inflammatory markers that are shown to be associated with illness presentation, symptom severity, and outcome in schizophrenia. Combining cost-effective, multimodal, clinically meaningful markers looks like a promising way forward toward individualized medicine.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95.
Ritsner M. The handbook of neuropsychiatric biomarkers, endophenotypes and genes: volume I: neuropsychological endophenotypes and biomarkers. Dordrecht: Springer; 2009.
Pillai A, Buckley PF. Reliable biomarkers and predictors of schizophrenia and its treatment. Psychiatr Clin North Am. 2012;35(3):645–59.
Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. Adv Drug Deliv Rev. 2010;62(11):1064–79.
Perkovic MN, Erjavec GN, Strac DS, Uzun S, Kozumplik O, Pivac N. Theranostic biomarkers for schizophrenia. Int J Mol Sci. 2017;18(4) pii: E733.
Light GA, Swerdlow NR. Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophrenia. Ann N Y Acad Sci. 2015;1344:105–19.
Carbon M, Correll CU. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci. 2014;16(4):505–24.
Diaz-Caneja CM, Pina-Camacho L, Rodriguez-Quiroga A, Fraguas D, Parellada M, Arango C. Predictors of outcome in early-onset psychosis: a systematic review. NPJ Schizophr. 2015;1:14005.
Stober G, Ben-Shachar D, Cardon M, Falkai P, Fonteh AN, Gawlik M, et al. Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J Biol Psychiatry. 2009;10(2):127–55.
Dazzan P, Arango C, Fleischacker W, Galderisi S, Glenthoj B, Leucht S, et al. Magnetic resonance imaging and the prediction of outcome in first-episode schizophrenia: a review of current evidence and directions for future research. Schizophr Bull. 2015;41(3):574–83.
Thermenos HW, Goldstein JM, Buka SL, Poldrack RA, Koch JK, Tsuang MT, et al. The effect of working memory performance on functional MRI in schizophrenia. Schizophr Res. 2005;74(2–3):179–94.
Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165(2):203–13.
Thibaut F, Boutros NN, Jarema M, Oranje B, Hasan A, Daskalakis ZJ, et al. Consensus paper of the WFSBP Task Force on Biological Markers: criteria for biomarkers and endophenotypes of schizophrenia part I: neurophysiology. World J Biol Psychiatry. 2015;16(5):280–90.
Figurov A, Pozzo-Miller LD, Olafsson P, Wang T, Lu B. Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus. Nature. 1996;381(6584):706–9.
Libman-Sokolowska M, Drozdowicz E, Nasierowski T. BDNF as a biomarker in the course and treatment of schizophrenia. Psychiatr Pol. 2015;49(6):1149–58.
Pickard BS. Schizophrenia biomarkers: translating the descriptive into the diagnostic. J Psychopharmacol. 2015;29(2):138–43.
Yamamori H, Hashimoto R, Fujita Y, Numata S, Yasuda Y, Fujimoto M, et al. Changes in plasma D-serine, L-serine, and glycine levels in treatment-resistant schizophrenia before and after clozapine treatment. Neurosci Lett. 2014;582:93–8.
Ohnuma T, Sakai Y, Maeshima H, Hatano T, Hanzawa R, Abe S, et al. Changes in plasma glycine, L-serine, and D-serine levels in patients with schizophrenia as their clinical symptoms improve: results from the Juntendo University Schizophrenia Projects (JUSP). Prog Neuro-Psychopharmacol Biol Psychiatry. 2008;32(8):1905–12.
Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, et al. Schizophrenia risk from complex variation of complement component 4. Nature. 2016;530(7589):177–83.
Sommer IE, de Witte L, Begemann M, Kahn RS. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? J Clin Psychiatry. 2012;73(4):414–9.
Akiibinu MO, Ogundahunsi OA, Ogunyemi EO. Inter-relationship of plasma markers of oxidative stress and thyroid hormones in schizophrenics. BMC Res Notes. 2012;5:169.
Scarr E, Millan MJ, Bahn S, Bertolino A, Turck CW, Kapur S, et al. Biomarkers for psychiatry: the journey from fantasy to fact, a report of the 2013 CINP Think Tank. Int J Neuropsychopharmacol. 2015;18(10):pyv042.
Prata D, Mechelli A, Kapur S. Clinically meaningful biomarkers for psychosis: a systematic and quantitative review. Neurosci Biobehav Rev. 2014;45:134–41.
Acknowledgments
This work is supported by the Department of Science and Technology (Government of India) Research Grant (DST/SJF/LSA-02/2014-15) to GV.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Dinakaran, D., Sreeraj, V.S., Venkatasubramanian, G. (2020). Biological Markers for Outcome and Recovery in Schizophrenia. In: Shrivastava, A., De Sousa, A. (eds) Schizophrenia Treatment Outcomes. Springer, Cham. https://doi.org/10.1007/978-3-030-19847-3_9
Download citation
DOI: https://doi.org/10.1007/978-3-030-19847-3_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-19846-6
Online ISBN: 978-3-030-19847-3
eBook Packages: Behavioral Science and PsychologyBehavioral Science and Psychology (R0)